OYST News and Press, Oyster Point Pharma Inc. From 06/21/21

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced t...

Oyster Point Pharma (OYST) announces enrollment of the first subject in the OLYMPIA Phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy ((NK)), a rare disease characterized by decreased corneal sensitivity and poor corneal ...

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced enrollment of the fir...

Oyster Point Pharma (OYST) has formed research collaboration with Adaptive Phage Therapeutics ((APT)) to leverage APT’s PhageBank technology for the development of potential treatments for multiple ophthalmic diseases. Under the terms of the agreement, Oyster Point Pharma has the optio...

Collaboration plans for developing biological therapies potentially targeting multiple ophthalmic diseases utilizing APT’s PhageBank™ technology Oyster Point Pharma plans to discuss the potential for bacteriophage in the treatment of ophthalmic diseases a...

Introduction of proprietary ETF™ Gene Therapy and first gene candidate, nerve growth factor (NGF), to target Stages 2 and 3 Neurotrophic Keratopathy (NK) Preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gl...

Oyster Point Pharma, Inc. (OYST) Q1 2021 Earnings Conference Call May 06, 2021 4:30 PM ET Company Participants Daniel Lochner - Chief Financial Officer Jeffrey Nau - President and Chief Executive Officer John Snisarenko - Chief Commercial Officer Conference Call Participants Ken Cacciatore - ...

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q1 2021 Earnings Call May 06, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q1 2021 Earnings Call Transcript...

Oyster Point Pharma (OYST): Q1 GAAP EPS of -$0.73 beats by $0.18.Press release. For further details see: Oyster Point Pharma EPS beats by $0.18

PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021 Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4 2021, if approved by the FDA OLYMPIA Phase 2 Study on Track, with Planned Enrollment of the First Patient in 1H 2021 Co...